

CBNPC (stades avancés) avec translocation ALK : inhibiteurs de tyrosine kinase en 1<sup>ère</sup> ligne

Références	Promoteur	Design	Sélection	Bras	N pts	R0	SSP (médiane)	Survie			p
								médiane	2 ans	5 ans	
<b>ITK vs chimio</b>											
2014 & 2018 Solomon (1,2)	Pfizer Oncology	Ph III R (ouverte) « PROFILE 1014 »	CBNPC non épidermoïde ALK-positifs	Crizotinib 250 mg po 2x/j	172	74 %	10,9 m	NA			NS
				Pemetrexed + cisplatine ou carboplatine	171	45 %	7,0 m	47,5 m			
2017 Soria (3)	Novartis	Ph III R (ouverte) « ASCEND-4 »	CBNPC non épidermoïde ALK-positifs	Ceritinib 750 mg po	189	72 %	16,6 m	NA	70,6%		NS
				Pemetrexed + cisplatine ou carboplatine	187	27 %	8,1 m	26,2 m	58,2%		
<b>Comparaison d'ITK</b>											
2017 & 2019 Peters & 2020 Mok (4–6)	F. Hoffmann–La Roche	Ph III R (ouverte) « ALEX »	CBNPC ALK-positifs	Crizotinib 250 mg po 2x/j	151	76 %	10,9 m	57,4 m		45,5 %	N
				Alectinib 600 mg po 2x/j	152	83 %	34,8 m	NA		62,5 %	
2017 Hida (7)	Chugai Pharmaceutical Co, Ltd.	Ph III R (ouverte) « J-ALEX »	CBNPC ALK-positifs	Crizotinib 250 mg po 2x/j	104	79 %	10,2 m				
				Alectinib 300 mg po 2x/j	103	92 %	NA				
2018 & 2020 Camidge (8,9)	Ariad Pharmaceuticals	Ph III R (ouverte) « ALTA-1L »	CBNPC ALK-positifs	Brigatinib 180 mg po	137	71 %	24 m	NA	76 %		NS
				Crizotinib 250 mg po 2x ;j	138	60 %	11 m	NA	74 %		
2019 Zhou (10)	F Hoffmann-La Roche	Ph III R (ouverte) « ALESIA »		Crizotinib 250 mg po 2x/j	62	77 %	11,1 m	12,6 m			NS
				Alectinib 300 mg po 2x/j	125	91 %	NA	14,7 m			
2020 Shaw (11)	Pfizer	« CROWN »	CBNPC ALK-positifs	Lorlatinib 100 mg po 1x/j	149	76 %	NA	NA			NS

				Crizotinib 250 mg po 2x/j	147	58 %	9,3 m	NA			

NA : non atteint

#### Références

1. Solomon BJ, Mok T, Kim D-W, Wu Y-L, Nakagawa K, Mekhail T, et al. First-Line Crizotinib versus Chemotherapy in *ALK* -Positive Lung Cancer. *New England Journal of Medicine*. 4 déc 2014;371(23):2167-77.
2. Solomon BJ, Kim D-W, Wu Y-L, Nakagawa K, Mekhail T, Felip E, et al. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in *ALK*-Mutation-Positive Non–Small-Cell Lung Cancer. *Journal of Clinical Oncology*. août 2018;36(22):2251-8.
3. Soria J-C, Tan DSW, Chiari R, Wu Y-L, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced *ALK* -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. *The Lancet*. mars 2017;389(10072):917-29.
4. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim D-W, et al. Alectinib versus Crizotinib in Untreated *ALK* -Positive Non–Small-Cell Lung Cancer. *New England Journal of Medicine*. 31 août 2017;377(9):829-38.
5. Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, et al. Updated Efficacy and Safety Data and Impact of the EML4-*ALK* Fusion Variant on the Efficacy of Alectinib in Untreated *ALK*-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study. *Journal of Thoracic Oncology*. juill 2019;14(7):1233-43.
6. Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim D-W, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced *ALK*-positive non-small-cell lung cancer in the ALEX study. *Annals of Oncology*. août 2020;31(8):1056-64.
7. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with *ALK* -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. *The Lancet*. juill 2017;390(10089):29-39.
8. Camidge DR, Kim HR, Ahn M-J, Yang JC-H, Han J-Y, Lee J-S, et al. Brigatinib versus Crizotinib in *ALK* -Positive Non–Small-Cell Lung Cancer. *New England Journal of Medicine*. 22 nov 2018;379(21):2027-39.

9. Camidge DR, Kim HR, Ahn M-J, Yang JCH, Han J-Y, Hochmair MJ, et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. *JCO*. 1 nov 2020;38(31):3592-603.
10. Zhou C, Kim S-W, Reungwetwattana T, Zhou J, Zhang Y, He J, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. *The Lancet Respiratory Medicine*. mai 2019;7(5):437-46.
11. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First-Line Lorlatinib or Crizotinib in Advanced *ALK* -Positive Lung Cancer. *N Engl J Med*. 19 nov 2020;383(21):2018-29.